The 1XX heading in this type record is an unestablished heading that is authorized for use as a subject subdivision with established headings.  Information about the subdivision term and/or established headings with which it is used may be contained in general note fields 667 and/or 680.  Subdivision records may contain 670 and 675 fields to justify the heading and usage.

LDR       * * * * *nz###22* * * * *n##4500

001       <control number>

003       <control number identifier>

005       19920520103200.0

008       

010  ##  $aex#87000001#

040  ##  $a<organization code>$c<organization code>

073  ##  $aA2$aA3$aA4$aA5$aA6$aA7$aA8$aA9$aA10$aA11$aA12
$aA13$aA14$aA15$aA16$aB1$aB3$aB4$aB5$aB6$aD8$aD12
$aG4$aG5$aG6$aG7$aG8$aG9$aG10$aG11$aG12$zmesh

180  ##  $xdrug effects

480  ##  $xDE

667  ##  $asubheading only; for effect of exogenously administered drugs & chemicals; includes their mechanism of action; see MeSH scope note in Introduction; indexing policy: Manual 19.8.24; DF: /drug eff or /DE

680  ##  $iUsed with organs, regions, tissues, or organisms and physiological and psychological processes for the effects of drugs and chemicals.

688  ##  $a66; used with Category A, B & G 1966; A, B, F & G 1967-74; A, B, F1-2 & G4-11 1975-81; A, B1, B3-6, F1-2 & G4-11 1982; A, B1, B3-6, F1-2 & G4-12 1983-86; A, B1, B3-6, F1-2, G4-12, BLOOD PROTEINS+, DNA+ & RNA+ 1987-88; A, B1, B3-6, F1-2, G4-12, BLOOD PROTEINS+ & NUCLEIC ACIDS+ 1989; A2-16, B1, B3-6, D12 & G4-12 1990 forward

See also:

Appendix B:  Full Record Examples

Appendices